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Abstract: The signaling pathway mediated by transforming growth
factor- (TGF-) participates in various biologic processes, includ-
ing cell growth, differentiation, angiogenesis, apoptosis, and extra-
cellular matrix remodeling. In the context of cancer, TGF- signal-
ing can inhibit tumor growth in early-stage tumors. However, in
late-stage tumors, the very same pathway promotes tumor invasive-
ness and metastasis. This paradoxical effect is mediated through
similar to mothers against decapentaplegic or Smad protein depen-
dent and independent mechanisms and provides an opportunity for
targeted cancer therapy. This review summarizes the molecular
process of TGF- signaling and the changes in inhibitory Smads that
contribute to lung cancer progression. We also present current
approaches for rational therapies that target the TGF- signaling
pathway in cancer.
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Transforming growth factor (TGF-) belongs to a super-family of structurally related polypeptides that also in-
cludes TGF-2, TGF-3, Activins, Nodals, and bone mor-
phogenetic (BMP) proteins.1,2 TGF- receptor I (TGF- RI)
is recruited to the complex by ligand binding to a heteromeric
complex of type I and type II (TGF- RII) receptors, which
are serine/threonine kinase transmembrane proteins. This
results in the activation of TGF- RII kinase domain in the
cytoplasm and then phosphorylates receptor-regulated Smad
proteins (R-Smad), Smad2 and Smad3. Activated phospho-
Smad2 and 3 bind with common mediated Smad (co-Smad),
Smad4, and translocate to the nucleus, which in turn regulates
transcription in a diverse array of genes (Figure 1).3 TGF-
signaling is subjected to negative feedback by two inhibitory
Smads (I-Smad), Smad6 and Smad7. Both I-Smads can
interfere the phosphorylation of Smad2/3 by interaction with
TGF- RI.4,5 The termination of TGF- signaling can also be
achieved through ubiquitination of TGF- RI and I-Smads by
ubiquitin ligases Smad ubiquitin regulatory factors 1 and 2
(Smurf1 and Smurf2), which promote polyubiquitination fol-
lowed by lysosomal-mediated degradation (Figure 1).6 In
addition to Smads mediated signaling, TGF- can also acti-
vate Smad-independent pathways in different cell contexts.7,8
TGF- and Cancer
Alterations in TGF- signaling are linked to a variety
of human diseases, including cancer and inflammation. Dis-
ruption of TGF- homeostasis occurs in several human can-
cers.9,10 Data from both experimental model systems and
studies of human cancers clearly show that not only the
ligand itself but also its downstream elements, including its
receptors and its primary cytoplasmic signal transducers, the
Smad proteins, are important in suppressing primary tumor-
igenesis in many tissue types.11 However, many human
cancers, including lung cancer, often overexpress TGF-.
Furthermore, TGF- enhances the invasiveness and meta-
static potential in certain late-stage tumors.12 The role of
TGF- in cancer progression and metastasis is generally
accompanied by decreased or altered TGF- responsiveness
and increased expression or activation of the TGF- ligand.12
In the immunocytochemical analysis, localization of secreted
TGF- is found at the advancing edges of primary tumors and
in lymph node metastases of human mammary carcinoma.13
High levels of TGF- were also detected in the serum of
patients with lung cancer and colorectal carcinomas com-
pared with nondiseased individuals, and TGF- level in
serum is deceased to normal range after surgical resection of
the tumor in colorectal cancer.14,15 This suggests that both
autocrine and paracrine effects of TGF- contribute to pro-
mote tumor progression.
Although most lung cancer cells secrete TGF-, the
malignant transformation in lung cancer results in a loss of
the tumor suppressor effects of TGF-. Loss of the TGF-
response, which results in lost of inhibitory effect of TGF-
on proliferation, has been associated with tumor development
and/or tumor progression in several cancers.16,17 Reduced
expression and inactivation of TGF- receptors were associ-
ated with loss of sensitivity with antiproliferative effects of
TGF- in carcinogenesis.11 In lung cancer, overexpression
of TGF- is associated with better prognosis in 5-year
patient survival.18 TGF-1 level in serum was elevated
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after radiotherapy in lung cancer, and the risk of radiation-
induced lung injury is associated with TGF-1 single
nucleotide polymorphism.19,20
I-Smads and TGF- Signaling
The feedback mechanisms that regulate TGF- signal-
ing play a central role in cellular homeostasis mediated by
TGF- (Figure 1). The transcriptional activation of I-Smads
is induced by TGF- and other signaling pathways such as
EGF, interferon gamma, and interleukin 1.21–23 I-Smads
(Smad6 and Smad7) regulate TGF- function by interfering
with receptor-mediated phosphorylation of Smad2/3.5,24 Gen-
erally, Smad6 is thought to repress BMP signaling, whereas
Smad7 represses the TGF- signaling pathway.21 However,
both proteins can regulate the TGF- signaling pathway
through negative regulation in lung epithelial cells.25 In lung
cancer, Smad6 is overexpressed in a portion of the tumors,
and high expression of Smad6 is associated with poor sur-
vival in patients with non-small cell lung cancer.26 Knock-
down of Smad6 in overexpressed lung cancer cells induced
apoptosis and growth arrest at the G1 phase, which contrib-
uted to the reestablishment of TGF- homeostasis in lung
cancer cells by reactivating the TGF- signal pathway.26
Similarly, overexpression of Smad7 causes malignant con-
version in multistage cancer models by cooperating with
oncogenic Ras and enhances tumorigenicity in pancreatic
cancer.27,28 Furthermore, stable expression of Smad7 impairs
bone metastasis in human melanoma cells and lung and liver
metastasis in JygMC(A) breast cancer cells.29,30 These studies
indicate that I-Smads play a critical role in tumorigenesis by
regulating TGF- homeostasis in normal and cancer cells.
Therapies targeting I-Smads could potentially help re-estab-
lish TGF- mediated growth inhibition in tumors and en-
hance patient survival.
Development of TGF- Signaling Inhibitors for
Cancer Treatment
TGF- suppresses early epithelial cancers by TGF--
mediated growth inhibition. As premalignant lesions
progress, TGF- signaling contributes to tumor progression
by inducing epithelial-to-mesenchymal transition (EMT),
thereby promoting the conversion of early epithelial tumors
to invasive, metastatic tumors.31 Many inhibitors of TGF-
signaling target the EMT process. For example, the small
molecule ATP competitive compounds SB-505124 and SB-
431542 have been developed as inhibitors against the enzy-
matic activity of the TGF- RI type receptor called activin
receptor-like kinase ALK5.32–34 These drugs have been
shown to inhibit TGF--induced cell migration and invasive-
ness in glioma or EMT in vitro.
In addition to small molecules, antibodies have been
developed. The TGF- antibody inhibits phosphatidylinositol-3
kinase (PI3K)/AKT activity in mammary cancer cells by neu-
tralizing TGF- protein and suppresses the growth of renal cell
carcinoma overexpressing TGF-.35,36 Antisense oligonucleo-
tides have been developed to directly target TGF-2 mRNA.
Recently, targeted TGF-2 suppression using AP 12009 has
emerged as a promising novel approach for treating malignant
gliomas and other highly aggressive TGF-2-overexpressing
tumors.37 Little studies have been done targeting TGF- signal-
ing pathway in lung cancer. However, our recent study suggests
that Smad6 protein contributes to lung cancer survival and
targeting Smad6 may serve as an effective means to reduce
tumor growth and improve patient outcome.26
CONCLUSION
TGF- signaling contributes to diverse cellular pro-
cesses and plays a critical role in lung cancer growth and
FIGURE 1. Schematic diagram of
transforming growth factor-
(TGF-) signaling pathway. TGF-
signaling is initiated by the binding
of TGF- to its receptors, transform-
ing growth factor- receptor I
(TGF- RI) and transforming growth
factor- receptor II (TGF- RII), and
receptor tyrosine kinase activation
which then phosphorylates
Smad2/3. Activated Smad2/3 regu-
lates gene expression of Smad4 and
other transcription factors (TF).
Feedback regulation is mediated by
Smad6/7, which interferes the bind-
ing of Smad2/3 to TGF- receptors
and inhibits transcription. Both
Smad6 and Smad7 are in turn in-
duced by TGF- and regulated by
Smad ubiquitin regulatory factors
(Smurfs). Synthetic inhibitors inacti-
vate the TGF- pathway by inhibi-
tion of receptor enzymatic activity.
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progression. TGF- generally serves as a negative growth
regulator in normal cells and early stage tumor development,
but it promotes tumor invasiveness and metastases by induc-
ing EMT and neoangiogenesis. Current strategies focus on
developing effective therapies that target mainly the tumor-
promoting activities of TGF- signaling. However, the com-
plex nature and dual effects of TGF- signaling in cancer
must be considered together to be effective in clinical trials
for cancer therapy. This requires combinational therapies that
seek to interfere with both TGF-/Smads dependent- and
independent-signaling processes.
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